Aaron Royston
Aaron Royston, MD, MBA, is Managing Partner at venBio, where he focuses on building and investing in innovative biotechnology companies. He has more than 15 years of experience in life sciences investing, company formation and operations, strategic and product planning in the biotechnology industry and clinical research.
In addition to Marrow, Dr. Royston has helped to launch, invest, and served on the board of a number of venBio companies including Apellis Pharmaceuticals (IPO 2017), Menlo Therapeutics (NASDAQ: APLS; IPO 2018), Akero Therapeutics (IPO 2019, acquired by Novo Nordisk), Harmony Biosciences (NASDAQ: HRMY; IPO 2020), Ventyx BioSciences (NASDAQ: VTYX; IPO 2021), RayzeBio (IPO 2023, acquired by BMS), Ablaze Pharmaceuticals (rights acquired by BMS), ViceBio (acquired by Sanofi), 35Pharma, Attovia Therapeutics (NASDAQ: ATTO; IPO 2026) and Candid Therapeutics (acquired by UCB). These companies have brought seven FDA-approved treatments to patients, addressing conditions ranging from rare genetic disorders to age-related macular degeneration.
Dr. Royston received a BS in biological sciences from Duke University, earned his MD from the University of Pennsylvania, and his MBA from the Wharton School.